Article
Santhera's drug gets US FDA nod for rare muscular dystrophy
Rating:
0.0
Views:
39
Likes:
1
Library:
1
Catalyst Pharmaceuticals said on Thursday that U.S. health regulators have approved its partner Santhera Pharmaceuticals' drug to treat Duchenne muscular dystrophy (DMD) in patients aged two years and older.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value